Which has grown faster, BFRI or IRIX?

Over the past five years, BFRI grew revenue faster — BFRI at a 15.55% CAGR versus IRIX at -0.57%.

Biofrontera Inc. (BFRI) vs IRIDEX Corporation (IRIX)

A side-by-side comparison of Biofrontera Inc. and IRIDEX Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

BFRI

Biofrontera Inc.

$11M

$0.87HealthcareDelayed quote: Oct 6, 2026, 10:03 AM EDT

IRIX

IRIDEX Corporation

$12M

$0.70HealthcareDelayed quote: Oct 6, 2026, 9:59 AM EDT

Total return — BFRI vs IRIX

growth of $100 · dividends reinvested · last 5y

BFRI -99.0% (-60.1%/yr)IRIX -90.9% (-38.0%/yr)IRIX compounded faster over this window

Log scale — wide-divergence pair

BFRI IRIX

BFRI vs IRIX: by the numbers

•IRIX is the larger company ($12M vs $11M market cap).
•Both run net losses; IRIX's is the smaller (-6.88% vs -13.78% net margin).
•BFRI grew revenue faster over the past five years (15.55% vs -0.57% CAGR).

Metrics side by side

Valuation

Metric	BFRI	IRIX
P/S ratio	0.24	0.23
P/B ratio	1.87	N/A

Profitability

Metric	BFRI	IRIX
Gross margin	84.45%	36.23%
Operating margin	-21.94%	-5.39%
Net margin	-13.78%	-6.88%
ROE	-106.87%	-97.47%
ROIC	-32.27%	-19.53%

Growth (annualized)

Metric	BFRI	IRIX
Revenue CAGR (5Y)	15.55%	-0.57%
Total return CAGR (5Y)	N/A	-38.13%

Frequently asked

Which has grown faster, BFRI or IRIX?: Over the past five years, BFRI grew revenue faster — BFRI at a 15.55% CAGR versus IRIX at -0.57%.

Go deeper

Full BFRI analysis Full IRIX analysis Interactive comparison tool

Dig into the metrics

Biofrontera ROE IRIDEX ROE Biofrontera operating margin IRIDEX operating margin Biofrontera revenue growth IRIDEX revenue growth Biofrontera free cash flow IRIDEX free cash flow

Biofrontera & IRIDEX appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.